BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences
November 07 2018 - 8:00AM
Highlights Preclinical Research and
Continued Progress of NurOwn® Platform in ALS Pivotal
Trial
BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading
developer of innovative autologous adult stem cell therapeutics for
debilitating neurodegenerative diseases, announced today that it
will highlight progress with ongoing preclinical research and their
proprietary NurOwn® technology platform at November clinical and
investor conferences.
Clinical Conferences
Neuroscience 2018 Conference, San Diego, CA
Date: |
November 7, 2018 |
Time: |
1:00-2:00pm |
Location: |
SDCC Halls B-H |
Session 761: |
Neurotoxicity,
Inflammation, Neuroprotection: Neuroprotective Mechanisms:
Preclinical (761.05 / MM14) |
Presenter: |
Ralph Kern, M.D., MHSc,
COO & CMO, Brainstorm Cell Therapeutics Inc. |
Poster: |
“Development of MSC-NTF
Cell Exosomes for Neurodegenerative Diseases.” |
More Information: Abstract of the poster is available here.
Investor Conferences
Inv€$tival Showcase, London, England— Chaim
Lebovits, President & CEO will provide a corporate update
presentation during the Jeffries-partnered Biotech & Money
Inv€$tival Showcase.
Date: |
November 13, 2018 |
Time:
|
11:00am |
Location: |
ADELPHI 2 |
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of
innovative autologous adult stem cell therapeutics for debilitating
neurodegenerative diseases. The Company holds the rights to
clinical development and commercialization of the NurOwn®
technology platform through an exclusive, worldwide licensing
agreement. NurOwn® has received Fast Track designation from the
U.S. Food and Drug Administration (U.S. FDA) in ALS and orphan
status by the U.S. FDA and the European Medicines Agency (EMA).
BrainStorm is currently enrolling a Phase 3 pivotal trial in ALS
(NCT03280056), investigating repeat-administration of NurOwn® at
six sites in the U.S., supported by a grant from the California
Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal
study is intended to support a filing for U.S. FDA approval of
NurOwn® in ALS. For more information, visit BrainStorm's website at
www.brainstorm-cell.com.
Safe-Harbor Statements
Statements in this announcement other than historical data and
information constitute "forward-looking statements" and involve
risks and uncertainties that could cause BrainStorm Cell
Therapeutics Inc.'s actual results to differ materially from those
stated or implied by such forward-looking statements. Terms and
phrases such as "may", "should", "would", "could", "will",
"expect", "likely", "believe", "plan", "estimate", "predict",
"potential", and similar terms and phrases are intended to identify
these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on
Form 10-Q available at http://www.sec.gov. These factors should be
considered carefully, and readers should not place undue reliance
on BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the
beliefs, expectations and opinions of management as of the date of
this press release. We do not assume any obligation to update
forward-looking statements to reflect actual results or assumptions
if circumstances or management's beliefs, expectations or opinions
should change, unless otherwise required by law. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.
CONTACT
Media:Joseph PetrozielloBrainStorm Cell TherapeuticsPhone:
+1.215.485.6797Email: JP@brainstorm-cell.com
Investors:Marcy Beth NanusSolebury TroutPhone:
+1.646.378.2927Email: MNanus@troutgroup.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2023 to Apr 2024